Honokiol

Honokiol: A Comprehensive Reference

1. Identity, Chemistry, and Natural Sources

Chemical Identity

Honokiol (3′,5-di-(2-propenyl)-1,1′-biphenyl-2,4′-diol) is a bioactive natural product derived from Magnolia spp. Its CAS registry number is [35354-74-6]. Its molecular formula is C₁₈H₁₈O₂, and it is classified as a biphenolic natural compound. Honokiol belongs to a class of neolignan biphenols. As a polyphenol it is relatively small and can interact with cell membrane proteins through intermolecular interactions like hydrogen bonding, hydrophobic interactions, or aromatic pi orbital co-valency. It is hydrophobic and readily dissolved in lipids.

Chemically, honokiol comprises two hydroxylated phenyl rings connected via a carbon–carbon bond, imparting amphipathic properties that enable membrane integration and significant blood–brain barrier (BBB) permeability — an unusual and advantageous feature for phytochemicals. It is structurally similar to propofol.

Botanical Sources

Honokiol is a lignan isolated from the bark, seed cones, and leaves of trees belonging to the genus Magnolia. Honokiol has been extracted from a number of species of Magnolia native to many regions of the globe. Magnolia grandiflora, which is native to the Southeastern United States, as well as Mexican species like Magnolia dealbata have been found to be sources of honokiol. Traditionally in Asian medicine, Magnolia biondii, Magnolia obovata, and Magnolia officinalis are commonly used.

The isomers magnolol and honokiol are the principal active components of magnolia bark extract, typically making up 1–10% of the dried bark, depending upon the species and the isolation methods. Honokiol is accompanied by other related polyphenols, including magnolol, with which it shares certain biologic properties. It has been identified as one of the chemical compounds in some traditional Eastern herbal medicines along with magnolol, 4-O-methylhonokiol, and obovatol.

Common Forms and Preparations

Honokiol is commercially available in several forms for research and supplemental use. Honokiol has found use in consumer products such as toothpastes and mouthwashes, anti-aging creams and as a nutritional supplement. Because of its poor aqueous solubility, advanced delivery systems have been developed: honokiol nanoemulsions have shown promising results in enhancing oral bioavailability and skin permeation in models of melanoma and psoriasis. Solid lipid nanoparticle (SLN) formulations have also been investigated; the oral bioavailability of honokiol-SLNs was found to be remarkably greater (8-fold) than a honokiol pure suspension.

2. Traditional and Historical Use

Traditional Chinese Medicine (TCM)

Traditional Chinese Medicine (TCM) has utilized Magnolia officinalis Rehder & E.H. Wilson (Chinese name: 厚朴, Hou Po) for over two millennia, primarily to "regulate Qi" and alleviate stagnation associated with digestive disorders, anxiety, and respiratory ailments. It was first documented in the Shennong Ben Cao Jing and later in the Ben Cao Gang Mu, emphasizing its role in harmonizing the stomach and relieving dampness.

Honokiol is the dominant biphenolic compound isolated from the Magnolia tree, and has long been considered as the active constituent of the traditional Chinese herb "Houpo," which is widely used to treat symptoms due to "stagnation of qi." In traditional Chinese medicine, magnolia bark is called Houpu and is most commonly taken from two species, Magnolia obovata and Magnolia officinalis.

Those who practice traditional Chinese medicine often harvest the bark in April and June, by peeling or cutting the bark from the roots, stems, and branches of the tree. While the stem barks are decocted to a slight extent in boiling water, the branch and root barks are dried in the shade. All these barks are then stacked up in a wet area. Once their inner surface turns dark brown or purplish brown, the TCM practitioners steam, roll, and dry them. This dried bark — known for its sharp smell and bitter taste — is then soaked in a traditional medicine tincture for oral use.

Japanese Kampo Medicine

Extracts from the bark and seed cones of Magnolia trees have been traditionally used in Chinese, Korean, and Japanese medicine as analgesics and treatments for anxiety and mood disorders, notably in formulas like Houpu in Chinese medicine and Kampo in Japan. Such herbal formulas include Houpu Tang, Xiao Zhengai Tang, Ping Wei San and Shenmi Tang from China, and Hange-koboku-to (Banxia Houpo Tang) and Sai-boku-to from Japan.

Today, magnolia bark is still used in these two traditional medicinal formulas: Banxia Houpo Tang, a Chinese formula said to move stagnant qi in the solar plexus, head, and throat area; and Saiboku-To, a Japanese formula with anti-inflammatory properties that can help to reduce asthma symptoms.

Historical Conditions Treated

Extracts from the bark or seed cones of the Magnolia tree have been widely used in traditional medicine in China, Korea, and Japan. Magnolia bark has traditionally been used in Eastern medicine as an analgesic and to treat anxiety and mood disorders. The bark of Magnolia officinalis contains biphenolic neolignans — principally honokiol and magnolol — which modern pharmacology has validated for multiple biological effects, including anxiolytic, anti-inflammatory, anticancer, and neuroprotective activities. Additional traditional indications included abdominal distension, warming and transforming phlegm, and helping to direct rebellious lung qi downwards, treating coughs, wheezing, and a stifling sensation in the chest.

3. Key Constituents and Active Compounds

Honokiol is the primary focus of modern pharmacological research derived from magnolia bark, though the bark itself contains a broader array of compounds. There are over 250 compounds found in the bark, flowers, and leaves; however, it is honokiol and magnolol that have received the most research attention. The two major active principles identified in Magnolia bark extracts are magnolol and honokiol, which are positional isomers.

Honokiol's established or well-studied molecular mechanisms include:

• GABA_A receptor positive allosteric modulation: Magnolol and honokiol enhanced both phasic and tonic GABAergic neurotransmission in hippocampal dentate granule neurons. All recombinant receptors examined were sensitive to modulation, regardless of the identity of the α, β, or γ subunit subtype, although the compounds showed particularly high efficacy at δ-containing receptors.
• NF-κB pathway inhibition: Honokiol has been shown to inhibit NF-κB activation through suppression of Akt and activation of IKK (inhibitor kinase), which then leads to phosphorylation and subsequent IκBα degradation.
• STAT3 inhibition: STAT3 is constitutively activated in many human cancer cells and can be inhibited by honokiol. Honokiol suppresses STAT3 activity induced by IL-6. Furthermore, STAT3 inhibition by honokiol has also been correlated with the repression of upstream protein tyrosine kinases c-Src, JAK1, and JAK2.
• PI3K/Akt/mTOR modulation: Honokiol's therapeutic promise is attributed to its ability to modulate critical signaling pathways including NF-κB, STAT3, PI3K/Akt/mTOR, and Nrf2.
• SIRT3 (mitochondrial sirtuin) activation: Honokiol is one of the most studied SIRT3 activators and is a natural lignan derived from the bark of Magnolia. Honokiol could increase SIRT3 expression and deacetylation activity, which have a favorable effect on heart disease, renal disease, surgery/anesthesia-induced cognitive decline, and vitiligo. For heart disease, honokiol activation of SIRT3 further decreases the acetylation levels of MnSOD2 and OSCP, resulting in improved mitochondrial rate of oxygen consumption and inhibition of ROS synthesis.
• Cannabinoid receptor activity: Studies have found that honokiol was a full agonist of CB1 (EC₅₀ >10 μM) and an inverse agonist of CB2. The naturally occurring derivative 4-O-methylhonokiol was shown to be a potent and selective cannabinoid CB2 receptor inverse agonist.
• Antioxidant / ROS scavenging: Honokiol has been proposed as an antioxidant. The compound protects against lipid peroxidation by interfering with ROS production and migration.
• Anti-inflammatory (cytokine suppression): Honokiol exhibits potent anti-inflammatory effects by suppressing the production of pro-inflammatory cytokines and inhibiting NF-κB signaling pathways.
• Neuroprotective (Na⁺/K⁺-ATPase and mitochondrial preservation): Honokiol results in neuronal protection through preservation of Na⁺/K⁺ ATPase, phosphorylation of pro-survival factors, preservation of mitochondria, and modulation of GABA_A. Honokiol further promotes neuronal health through prevention of glucose, ROS, and inflammatory-mediated damage.
• Antithrombotic: Honokiol inhibits platelet aggregation in rabbits in a dose-dependent manner, and protects cultured endothelial cells against oxidized low-density lipoprotein injury.

4. Pharmacokinetics and Bioavailability

As a highly lipophilic biphenolic lignan (aqueous solubility ≈0.013 mg/mL), honokiol undergoes poor gastrointestinal absorption, with reported oral bioavailability of only approximately 4–5% in rodents. Honokiol suffers from erratic absorption and first-pass hepatic metabolism, resulting in subtherapeutic plasma levels and insufficient tissue distribution when administered in free form.

When honokiol was administered orally to rats at a dosage of 40 mg/kg, its highest concentration in plasma was observed within a short span of 20 minutes. The compound then undergoes quick metabolism to form mono-glucuronidated honokiol and is eliminated at a moderate pace with a half-life of approximately 290 minutes.

In a comparative study, plasma honokiol concentrations were maintained above 30 and 10 μg/mL for 24 and 48 hours, respectively, in liposomal honokiol-treated mice, whereas they fell quickly (less than 5 μg/mL) by 12 hours in free honokiol-treated mice bearing A549 xenograft tumors. Organ distribution of honokiol was revealed to be in the following order: lungs > plasma > liver > brain > kidney > heart > spleen, following treatment of animal models.

Because of its physical properties, honokiol can readily cross the blood–brain barrier and the blood–cerebrospinal fluid barrier. As a result, honokiol is a potentially potent therapy with high bioavailability in neurological tissues. While its pharmacokinetics have been studied in rodent models, these parameters have yet to be fully defined in humans.

5. Scientific Evidence by Area of Use

5.1 Anxiety and Sedation

Preclinical evidence (animal/in vitro): Both magnolol and honokiol have been identified as neurologically active agents, with anxiolytic, sedative, neuroprotective, and anti-convulsant actions in animal models. It is believed that honokiol acts on GABA_A receptors similarly to benzodiazepines and Z-drugs. However, honokiol has been shown to achieve anxiolysis with fewer motor or cognitive side effects than GABA_A receptor agonists such as flurazepam and diazepam. It has been shown that honokiol likely has a higher selectivity for different GABA_A receptor subtypes and both magnolol and honokiol showed higher efficacy when acting on receptors containing δ subunits.

This direct positive modulation of both synaptic and extra-synaptic populations of GABA_A receptors suggests that supplements containing magnolol and/or honokiol would be effective anxiolytics, sedatives, and anti-convulsants.

Human/clinical evidence: Preclinical evidence is strong for anxiety, sleep, and neuroprotection, though human clinical trials of isolated honokiol remain limited. The available human data involve magnolia bark extract preparations rather than isolated honokiol, and the evidence base for clinical anxiolytic efficacy in humans is thus considered preliminary.

5.2 Neuroprotection, Neurodegenerative Disease, and Cognitive Function

Preclinical evidence: Neuroprotective effects of honokiol have been demonstrated in models of Alzheimer's disease, Parkinson's disease, and ischemic brain injury, where honokiol attenuated neuroinflammation, improved mitochondrial function, and preserved cognitive performance.

In preclinical models of Alzheimer's disease, honokiol showed promise in lowering the production of amyloid-beta (Aβ) plaques, phosphorylating tau, and enhancing cognitive performance. Honokiol also demonstrated promise in preventing the degradation of dopaminergic neurons in Parkinson's disease and improving motor function.

In AD animals, honokiol (HKL) has been found to be effective in ameliorating cognitive impairment and alleviating Aβ deposition and neuroinflammation in the cortex and hippocampus. The ameliorative effect of HKL on memory impairment and its repression on glial cell activation have been suggested as primary ways to relieve Alzheimer's disease. Significantly suppressed Aβ plaque formation, neuroinflammation, and neuronal loss have been discovered in AD rats treated with HKL.

In cerebrovascular ischemia-reperfusion models: intravenous treatment with honokiol (0.01–1.0 μg/kg) in rats 15 minutes before and 60 minutes after middle cerebral artery occlusion (MCAO) reduced infarct volume by 20–70% in a dose-dependent manner. It also reduced lipid peroxidation (MDA) and neutrophil infiltration into brain tissue.

A dose-dependent toxicity caveat is important: while honokiol has been found to have neuroprotective effects at low doses, it has also been found to increase neuronal death in vitro at higher doses (100 μM applied directly to fetal cortical neurons).

Human/clinical evidence: Honokiol is beneficial in several mouse models of neurodegeneration, but specialized formulations to increase bioavailability may be needed. No controlled human clinical trials specifically assessing honokiol for neurodegenerative outcomes have been published as of the available literature. Evidence remains at the preclinical stage.

5.3 Oncology / Cancer

Preclinical evidence (extensive): Honokiol exerts potent anticancer effects through the inhibition of tumor proliferation, induction of cell cycle arrest and apoptosis, and suppression of metastasis and angiogenesis in diverse malignancies such as breast, colon, prostate, lung, and glioblastoma. Honokiol has demonstrated potent antitumor effects across multiple cancer models — including breast, lung, prostate, liver, and colorectal cancers — through mechanisms such as apoptosis induction, angiogenesis inhibition, immune modulation, and suppression of tumor cell proliferation and metastasis.

In lung cancer specifically: honokiol's mechanism of action is mediated primarily by inhibiting the STAT3 pathway. Honokiol specifically inhibits STAT3 phosphorylation irrespective of the mutation status of EGFR, and knockdown of STAT3 abrogated both the anti-proliferative and the anti-metastatic effects of honokiol.

In head and neck squamous cell carcinoma (HNSCC) cell lines: honokiol inhibited tumor cell proliferation (half maximal effective concentration: 3.3–7.4 μM), induced apoptosis, and suppressed key EGFR downstream signaling pathways including MAPK, AKT, and STAT3. Honokiol also enhanced the efficacy of erlotinib, leading to significant tumor growth inhibition in vivo.

Regarding combination with cisplatin: pharmacological studies indicate that combining cisplatin with honokiol significantly enhances its therapeutic efficacy while reducing side effects, particularly in colorectal and ovarian cancer. Honokiol has been shown to regulate the IL-6/STAT3 signaling pathway in oral carcinoma stem cells, sensitizing cancer cells to cisplatin.

Honokiol crosses the blood–brain barrier and blood–cerebrospinal fluid barrier, and inhibits brain tumor growth in animal models of intracerebral gliosarcoma.

Human/clinical evidence: Honokiol was well tolerated in multiple animal models when administered orally, intravenously, and via intraperitoneal route. However, there are limited human data on the use of honokiol in general, and specifically via IV in cancer. A published case report (PMC7268168) described two cancer patients who received intravenous honokiol as part of their treatment regimen. The initial infusion of honokiol was 10 mg/kg body weight, and subsequent treatments were increased up to 50 mg/kg according to individual tolerance, over 2 weeks. A honokiol liposome formulation was reported to be planned for testing in a Phase 1 clinical trial (CTR20170822) in China. Overall, the oncological evidence for honokiol in humans is at an early, case-report-level stage, and well-powered randomized clinical trials have not been completed.

5.4 Cardiovascular System

Preclinical evidence: Honokiol suppresses cardiac hypertrophy and fibrosis via SIRT3-regulated AKT and ERK1/2 inhibition in mice with cardiac hypertrophy. Furthermore, in mice with doxorubicin-induced cardiomyopathy, honokiol activated SIRT3 to promote mitochondrial fusion and inhibit apoptosis. Honokiol is beneficial in mouse models of several age-related diseases such as cardiovascular disease.

Human/clinical evidence: There are no published controlled clinical trials directly assessing honokiol's cardiovascular effects in humans. The existing evidence is entirely from animal and cell-based models.

5.5 Metabolic Effects (Diabetes and Obesity)

Preclinical evidence: Honokiol shows anti-diabetic properties through enhancing insulin sensitivity, and anti-obesity properties through promoting browning of adipocytes. The SIRT3 activator honokiol induced adipogenesis compared to control. Honokiol increased expression of adipocyte gene markers, genes involved in lipolysis, and glucose transport (GLUT4).

Regarding liver lipid metabolism: honokiol (HK) attenuates lipid accumulation in lipotoxic hepatocytes through promoting SIRT3-AMPK-induced autophagy and mitochondrial function.

Human/clinical evidence: Evidence in this domain remains exclusively preclinical (cell-culture and animal model). No clinical trials in human diabetic or obese populations have been reported.

5.6 Anti-inflammatory and Autoimmune Effects

Preclinical evidence: Studies have demonstrated honokiol's efficacy in ameliorating inflammatory conditions such as arthritis, colitis, and dermatitis in preclinical models. Honokiol blocks inflammatory factor production in glial cells through the inhibition of NF-κB activation. This mechanism is believed to suppress production of NO, tumor necrosis factor-α (TNF-α), and RANTES/CCL5.

Human/clinical evidence: Controlled human trials specifically targeting inflammatory or autoimmune conditions with honokiol have not been reported.

5.7 Antimicrobial Activity

Preclinical evidence: Honokiol showed potent antibacterial activity against a number of Gram-positive bacteria including MRSA and VRE. Moreover, honokiol in combination with clinically used β-lactam antibiotics exhibits strong synergistic antimicrobial effects against drug-resistant S. aureus strains. Honokiol at 10 μg/mL was found to inhibit biofilm formation of MRSA 41573 and, at 50 μg/mL, it disrupted the mature biofilm.

Human/clinical evidence: A 30-day clinical trial in a dental context is the most directly relevant human study. In a 30-day clinical trial with 40 participants, no significant side effects were found from daily doses of 11.9 mg of honokiol. However, this trial assessed safety and local antimicrobial effects rather than systemic infection outcomes, and the evidence for clinical systemic antimicrobial use remains preclinical.

6. Body Systems and Health Areas Associated with Honokiol

Honokiol is a pleiotropic natural compound under preliminary research for antitumor, anti-inflammatory, antioxidant, neuroprotective, and antithrombotic properties, showing therapeutic potential across the central nervous system, cardiovascular system, and gastrointestinal system. The principal body systems for which scientific evidence — even if predominantly preclinical — has been generated are:

• Central Nervous System: Anxiolysis, sedation, neuroprotection, anticonvulsant effects, pain modulation, Alzheimer's and Parkinson's disease models.
• Cardiovascular System: Antithrombotic, antiarrhythmic, cardioprotective (SIRT3-dependent), anti-cardiac hypertrophy.
• Oncology: Multi-cancer-type antitumor activity via apoptosis, anti-angiogenesis, anti-metastasis (preclinical only).
• Metabolic / Endocrine: Insulin sensitization, adipogenesis modulation, hepatic lipid regulation (SIRT3/AMPK axis).
• Immune / Inflammatory: Suppression of NF-κB-mediated inflammation, anti-arthritic, anti-colitis.
• Gastrointestinal: Historically used for abdominal distension and digestive disorders; some preclinical gastrointestinal protective data.
• Antimicrobial: Activity against Gram-positive bacteria including drug-resistant strains.

7. Dosage Forms and Dosages Reported in Studies

Honokiol has been studied across a range of administration routes and dose levels, primarily in preclinical models. The following dosages are cited directly from source materials:

• Oral (rat model, pharmacokinetics): When honokiol was administered orally to rats at a dosage of 40 mg/kg, its highest concentration in plasma was observed within a short span of 20 minutes.
• Intravenous (rat ischemia model): Intravenous treatment with honokiol at 0.01–1.0 μg/kg in rats was administered 15 minutes before and 60 minutes after MCAO.
• Intraperitoneal (mouse TBI model): Rats were subjected to TBI and treated with honokiol at 5 mg/kg/day intraperitoneally for seven days.
• Intravenous (human case reports, drug-resistant cancer): The initial infusion of honokiol was 10 mg/kg body weight, and subsequent treatments were increased up to 50 mg/kg according to individual tolerance, over 2 weeks.
• Oral (human clinical trial, dental/safety study): In a 30-day clinical trial with 40 participants, no significant side effects were found from daily doses of 11.9 mg of honokiol.
• Oral supplement (human study, combined preparation): Two human studies used a supplement containing the equivalent of approximately 11.25 mg of honokiol and 0.75 mg of berberine.

It should be noted that standardized, clinically validated dosage recommendations for isolated honokiol in humans do not currently exist in the peer-reviewed literature for any therapeutic indication.

8. Safety, Toxicology, and Drug Interactions

General Toxicological Profile

Toxicological studies on honokiol and Magnolia bark extract have not shown any pathologic changes in the liver, lung, kidney, spleen, brain, heart, pancreas, intestines, or bone marrow after systemic or oral administration, suggesting its safety.

In vitro and in vivo genotoxicity studies indicated that concentrated magnolia bark extract (MBE) has no mutagenic and genotoxic potential, while a subchronic study performed according to OECD guidelines established a no-adverse-effect level for concentrated MBE >240 mg/kg body weight/day. Intervention trials employing concentrated MBE for up to 1 year did not report adverse effects.

However, some caveats exist: one toxicology study of a methanol extract of Magnolia officinalis (equivalent to 2 mg/day of honokiol) over three months in mice suggested some changes in clinical parameters related to kidney function and there were alterations in kidney ultrastructure morphology.

There is insufficient data in humans on whether honokiol would be safe for long-term use. The safety of honokiol in humans is currently unknown.

Antithrombotic / Bleeding Risk

Honokiol may pose bleeding risks in patients with hemophilia, Von Willebrand disease, or those on anticoagulant therapy. This concern arises from its established antiplatelet mechanism of action in preclinical models.

Cytochrome P450 and Drug-Metabolizing Enzyme Interactions

The inhibitory potentials of honokiol on eight major human cytochrome P450 (CYP) enzymes (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) and four UDP-glucuronosyltransferases (UGTs) in human liver microsomes were investigated. Honokiol strongly inhibited CYP1A2, CYP2C8, CYP2C9, CYP2C19, and UGT1A9 with Ki values of 1.2, 4.9, 0.54, 0.57, and 0.3 μM, respectively.

Honokiol also moderately inhibited CYP2B6 and CYP2D6 with Ki values of 17.5 and 12.0 μM, respectively. These in vitro results indicate that honokiol has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, CYP2C8, CYP2C9, CYP2C19, and UGT1A9.

It is important to note that the inhibition of CYP activities in vitro does not necessarily translate into drug interactions in clinical situations. Thus, clinical trials to evaluate the inhibitory effects of honokiol on CYP1A2, CYP2C8, CYP2C9, CYP2C19, and UGT1A9 should be conducted.

Regarding enzyme induction: honokiol is a weak CYP2B6 inducer and is unlikely to increase the metabolism of concomitant CYP2B6 substrates and cause pharmacokinetic-based drug interactions in humans at physiologically relevant concentrations.

Metabolism and Glucuronidation

Similar to other dietary polyphenols, magnolol and honokiol are subject to glucuronidation, and despite a relatively quick clearance, an interaction with pharmaceutical active principles or other herbal constituents cannot be excluded.

Summary of Evidence Strength

The body of available research on honokiol is large in volume but predominantly preclinical (in vitro and animal studies). Pharmacological studies have shown that honokiol possesses a wide range of bioactivities without obvious toxicity in these models. However, translation to validated human clinical outcomes remains very limited. The most well-documented human data consist of a single 30-day dental safety study (n=40), case reports of intravenous use in oncology, and several human trials using whole magnolia bark extract preparations that contain honokiol alongside other constituents. Robust, double-blind, randomized controlled trials of isolated honokiol in any specific human indication have not been published.

References

• Arora S et al. "Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets." PubMed (2019).
• Arora S et al. "Honokiol: a novel natural agent for cancer prevention and therapy." PMC / Cancer Letters (2012).
• Wang X et al. "Honokiol: A naturally occurring lignan with pleiotropic bioactivities." PubMed (2021).
• Banik NL et al. "Honokiol, a multifunctional antiangiogenic and antitumor agent." PubMed (2009).
• Tahir RA et al. "Honokiol as a next-generation phytotherapeutic: Anticancer, neuroprotective, and nanomedicine perspectives." ScienceDirect (2025).
• Wikipedia. "Honokiol." (accessed 2026).
• Woodbury A et al. "Neuro-Modulating Effects of Honokiol: A Review." Frontiers in Neurology (2013).
• Woodbury A et al. "Neuro-Modulating Effects of Honokiol: A Review." PMC (2013).
• Alexeev M et al. "The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABA(A) receptors." PubMed (2012).
• Alexeev M et al. "The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABAA receptors." Neuropharmacology (2012).
• Jeong HU et al. "Effect of Honokiol on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes." PMC / Molecules (2018).
• Jeong HU et al. "Effect of honokiol on the induction of drug-metabolizing enzymes in human hepatocytes." PubMed (2014).
• Poivre M, Duez P. "Safety and Toxicology of Magnolol and Honokiol." PubMed (2017).
• Liet al. "Intravenous Honokiol in Drug-Resistant Cancer: Two Case Reports." PMC (2020).
• Alzheimer's Drug Discovery Foundation. "Honokiol — Cognitive Vitality Report." (accessed 2024).
• He M et al. "Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target." PMC (2020).
• Athari Nik Azm S et al. "Sirt3 Pharmacologically Promotes Insulin Sensitivity through PI3/AKT/mTOR in Adipocytes." PMC / MDPI IJMS (2022).
• Li et al. "Honokiol attenuates lipotoxicity in hepatocytes via activating SIRT3-AMPK mediated lipophagy." PMC (2021).
• Sun X et al. "The study of honokiol as a natural product-based antimicrobial agent and its potential interaction with FtsZ protein." PMC / Frontiers in Microbiology (2024).
• Lin L et al. "Honokiol Decreases Lung Cancer Metastasis through Inhibition of the STAT3 Signaling Pathway." PMC (2018).
• Chen et al. "Honokiol in cancer: Roles in enhancing combination therapy efficacy and preventing post-transplant malignancies." PMC (2025).
• Zhang et al. "Honokiol inhibits gastric cancer via tumor microenvironment modulation: a bioinformatics and single-cell analysis." Scientific Reports (2025).
• Jahan R et al. "Nature's neuroprotector: Honokiol and its promise for Alzheimer's and Parkinson's." ScienceDirect (2025).
• Li X et al. "Honokiol relieves hippocampal neuronal damage in Alzheimer's disease by activating the SIRT3-mediated mitochondrial autophagy." PMC / CNS Neuroscience & Therapeutics (2024).
• Guo L et al. "Nanotechnology-Based Drug Delivery Systems for Honokiol: Enhancing Therapeutic Potential and Overcoming Limitations." PMC (2023).
• Liu Y et al. "Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update." Frontiers in Pharmacology (2021).